摘要
目的探讨利妥昔单抗联合CHOP治疗初治B细胞非霍奇金淋巴瘤(NHL)的近期疗效和毒副反应。方法 65例初治B细胞NHL随机分为两组,观察组35例接受利妥昔单抗联合CHOP方案治疗,对照组30例仅接受CHOP方案化疗,并比较观察两组的近期疗效和毒副反应。结果观察组总有效率及临床获益率分别为71.43%、94.29%,均高于对照组的50.00%、70.00%,差异有统计学意义(P均<0.05)。观察组出现3例利妥昔单抗相关的轻度发热。两组化疗相关毒副反应均较轻,且发生率比较差异均无统计学意义(P均>0.05)。所有毒副反应均未影响治疗的顺利进行。结论利妥昔单抗联合CHOP方案治疗初治B细胞NHL疗效较单纯CHOP方案好,但毒副反应未增加,值得临床推广应用。
Objective To investigate the short term efficacy and toxicities of rituximab combined with CHOP regimen in the treatment of the initial patients with B-cell non-Hodgkin lymphoma （NHL）. Methods Sixty-five initial patients with B-cell NHL were randomly divided into two groups,35 patients of the observation group were treated with rituximab combined with CHOP regimen,30 patients of the control group were treated with only CHOP chemotherapy,and the efficacy and toxicities were compared. Results The total response rate and the clinical benefit rate were 71.43% and 94.29%,and were 50.00% and 70.00% in the control group （P 〈 0.05）. The rituximab-related mild fever was observed in the 3 patients. The toxicities related to chemotherapy were mild in the two groups,there was no statistical differences in the incidences between the two groups （P 〉 0.05）. Conclusion Rituximab combined with CHOP regimen has better efficacy in the treatment of the patients with B-cell NHL,but the toxicities doesn＇t increased.
出处
《中国医药科学》
2013年第13期40-41,68,共3页
China Medicine And Pharmacy
